Ventyx Biosciences to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
06 Fevereiro 2024 - 6:05PM
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a
clinical-stage biopharmaceutical company focused on advancing novel
oral therapies that address a broad range of inflammatory diseases
with significant unmet medical need, today announced that Company
executives will participate in the upcoming Oppenheimer 34th Annual
Healthcare Life Sciences Conference.
- Event: Oppenheimer 34th Annual Healthcare Life Sciences
Conference Location: VirtualDate: Tuesday, February
13, 2024Time: 11:20-11:50 AM ET
A webcast of the presentation will be available
in the Investors and News section of the Ventyx website at
www.ventyxbio.com. A webcast replay will also be available on this
website shortly after conclusion of the event for thirty days.
About Ventyx Biosciences
Ventyx is a clinical-stage biopharmaceutical
company focused on developing innovative oral medicines for
patients living with autoimmune and inflammatory disorders. We
believe our ability to efficiently discover and develop
differentiated drug candidates will allow us to address important
unmet medical need with novel oral therapies that can shift
immunology markets from injectable to oral drugs. Our current
pipeline includes internally discovered clinical programs targeting
TYK2, S1P1R and NLRP3, positioning us to become a leader in the
development of oral immunology therapies. Ventyx is headquartered
in San Diego, California. For more information about Ventyx, please
visit www.ventyxbio.com.
Investor Relations ContactPatti BankManaging
DirectorICR Westwicke(415) 513-1284IR@ventyxbio.com
Ventyx Biosciences (NASDAQ:VTYX)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Ventyx Biosciences (NASDAQ:VTYX)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024